Clinically isolated syndrome and multiple sclerosis: Rethinking the arsenal

Current Treatment Options in Neurology

Volumn 11, Issue 3, 2009, Pages 193-202

  Pandey, Krupa ^b   Lublin, Fred D ^a  

^a Department of Neurology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ALEMTUZUMAB; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; ANTICONVULSIVE AGENT; BACLOFEN; BETA INTERFERON; BETA1A INTERFERON; BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCIUM; CARBAMAZEPINE; COLECALCIFEROL; FINGOLIMOD; GABAPENTIN; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; MODAFINIL; NATALIZUMAB; OXYBUTYNIN; PLACEBO; RITUXIMAB; SEROTONIN UPTAKE INHIBITOR; TIZANIDINE; TOLTERODINE; UNINDEXED DRUG; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANEMIA; ANXIETY; BLADDER DYSFUNCTION; BRAIN DEPTH STIMULATION; BRAIN DISEASE; CARDIOTOXICITY; CHEST TIGHTNESS; CLINICAL TRIAL; CLINICALLY ISOLATED SYNDROME; COGNITIVE DEFECT; DEMYELINATION; DEPRESSION; DETRUSOR MUSCLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; EOSINOPHILIA; FATIGUE; FLACCID PARALYSIS; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HEART PALPITATION; HERPES VIRUS INFECTION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCONTINENCE; INFECTION; INJECTION SITE REACTION; KINESIOTHERAPY; LEUKEMIA; LEUKOPENIA; LIPOATROPHY; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYALGIA; NEUROPROTECTION; NEUTROPENIA; PAROXYSMAL DYSTONIA; PHYSIOTHERAPY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOTHERAPY; RELAPSE; RETINA MACULA EDEMA; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SPASTICITY; SPEECH THERAPY; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WEAKNESS; XEROSTOMIA;

EID: 64549158395     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-009-0023-7     Document Type: Review

References (54)

1. Orton SM, Herrera BM, Yee, IM, et al.: Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol 2006, 5:932-936.
2. Richards RG, Sampson FC, Beard SM, Tappenden P: A review of the natural history and epidemiology of multiple sclerosis: Implications for resource allocation and health economic models. Health Technol Assess 2002, 6:1-73.
3. Polman CH, Reingold SC, Edan G, et al.: Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005, 58:840-846.
4. Confavreux C, Aimard G, Devic M: Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980, 103:281-300.
5. Poser S, Bauer HJ, Poser W:RPrognosis of multiple sclerosis: results from an epidemiological area in Germany. Acta Neurol Scand 1982, 65:347-354.
6. Weinshenkar BG, Bass B, Rice GP, et al.: The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 1989, 112:133-146.
7. Lublin FD, Reingold SC: Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1997, 48:572-574.
8. Soilu-Hänninen M, Airas L, Mononen I, et al.: 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005, 11:266-271.
9. Tremlett H, van der Mei IA, Pittas F, et al.: Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008, 31:271-279.
10. Munger KL, Levin LI, Hollis BW, et al.: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
11. Burton JM, Kimball S, Vieth R, et al.: A phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis. Program and abstracts of the ECTRIMS 2008: 24th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Montreal, Canada. September 17-20, 2008.
12. Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta 1-a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898-904.
13. Comi G, Filippi M, Barkhof F, et al.; Early Treatment of Multiple Sclerosis Study Group: Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet 2001, 357:1576-1582.
14. Kappos L, Polman CH, Freedman MS, et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
15. The IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
16. Jacobs LD, Cookfair DL, Rudick RA, et al.: Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285-294.
17. Ebers GC, PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
18. Durelli L, Verdun E, Barbero P, et al.; Independent Comparison of Interferon (INCOMIN) Trial Study Group: Every other day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet 2002, 359:1453-1460.
19. Panitch H, Goodin DS, Francis G, et al.: Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002, 59:1496-1506.
20. Goodin DS, Frohman EM, Hurwitz B, et al.: Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007, 68:977-984.
21. Johnson KP, Brooks BR, Cohen JA, et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
22. Johnson KP, Brooks BR, Cohen JA, et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998, 50:701-708.
23. Mikol DD, Barkhof F, Chang PK, et al.: Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008, 7:903-914.
24. The BEYOND (Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose) Study. Available at http://www.pharma.bayer.com/scripts/pages/en/ news_room/news_room/news_room38.php. Accessed February 2, 2009.
25. Combination therapy in patients with relapsing-remitting multiple sclerosis (MS): CombiRx. Available at http://clinicaltrials.gov/ct2/show/ NCT00211887?term=multiple+sclerosis+combination+therapy&age= 1&fund=0&rank=1. Accessed February 2, 2009.
26. Polman CH, O'Connor PW, Havrdova E, et al., for the AFFIRM investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
27. Hyman N, Barnes M, Bhakta B, et al.: Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomized, double-blind, placebo controlled dose ranging study. J Neurol Neurosurg Psychiatry 2000, 68:707-712.
28. Schurch B, De Seze M, Denys P, et al.: Botulinum toxin A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo-controlled 6-month study. J Urol 2005, 174:196-200.
29. Smith CP, Nishiguchi J, O'Leary M, et al.: Single institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. J Urol 2005 65:37-41.
30. Schuele SU, Kellinghaus C, Shook SJ, et al.: Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005, 64:1086-1087.
31. Alusi SH, Worthington J, Glickman S, Bain PG: A study of tremor in multiple sclerosis. Brain 2001, 124:720-730.
32. Alusi SH, Aziz TZ, Glickman S, et al.: Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: A prospective case-controlled study. Brain 2001, 124:1576-1589.
33. Schuurman PR, Bosch DA, Bossuyt PM, et al.: A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000, 342:461-468.
34. Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G: Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev 2005, CD003980.
35. Goodman AD, Brown TR, Cohen JA, et al.: Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008, 71:1134-1141.
36. Andrews KL, Husmann DA: Bladder dysfunction and management in multiple sclerosis. Mayo Clin Proc 1997, 72:1176-1183.
37. Arnett PA, Barwick FH, Beeney JE: Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc 2008, 14:691-724.
38. Efficacy and safety of fingolimod in patients With relapsing-remitting multiple sclerosis with optional extension phase (TRANSFORMS). Available at http://www.clinicaltrials.gov/ct2/show/NCT00340834?term= TRANSFORMS&rank=1. Accessed January 27, 2009.
39. FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS). Available at http://www.clinicaltrials.gov/ct2/show/ NCT00731692?term=FTY720&rank=1. Accessed January 27, 2009.
40. Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis (FREEDOMS II). Available at http://www.clinicaltrials.gov/ct2/show/ NCT00355134?term=fty720&recr=Open&rank=5. Accessed January 27, 2009.
41. The CAMMS223 Trial Investigators: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
42. Comparison of alemtuzumab and Rebif multiple sclerosis, Study Two (CARE-MS II). Available at http://www.clinicaltrials.gov/ct2/show/ NCT00548405?term=alemtuzumab&rank=58. Accessed January 27, 2009.
43. Hauser SL, Waubant E, Arnold DL, et al.: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
44. CLARITY - Safety and efficacy of oral cladribine in subjects with relapsing-remitting MS. Available at http://www.clinicaltrials.gov/ct2/ show/NCT00213135?term=cladribine+and+multiple+sclerosis&rank=3. Accessed January 27, 2009.
45. Phase II cladribine add-on to interferon-beta (IFN-β) therapy in MS subjects with active disease (ONWARD). Available at http://www.clinicaltrials.gov/ct2/show/NCT00436826?term=cladribine+and+ multiple+sclerosis&rank=2. Accessed January 27, 2009.
46. Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO). Available at http://www.clinicaltrials.gov/ct2/show/NCT00134563?term= teriflunomide+and+multiple+sclerosis&rank=4. Accessed January 27, 2009.
47. Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis. Available at http://www.clinicaltrials.gov/ct2/show/NCT00622700?term=teriflunomide+and +multiple+sclerosis&rank=1. Accessed January 27, 2009.
48. Weinshenker BG, O'Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878-886.
49. Nishikawa M, Ichiyama T, Hayashi T, et al.: Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol 1999, 21:583-586.
50. Murthy SN, Faden HS, Cohen ME, Bakshi R: Acute disseminated encephalomyelitis in children. Pediatrics 2002, 110(2 Pt 1):e21.
51. Apak RA, Anlar B, Saatci I: A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 1999, 21:279-282.
52. Banwell B, Reder AT, Krupp L, et al.: Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006, 66:472-476.
53. Ghezzi A, Amato MP, Capobianco M, et al.: Disease modifying drugs in childhood-juvenile multiple sclerosis: Results of an Italian co-operative study. Mult Scler 2005, 11:420-424.
54. Banwell B: Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother 2005, 5:391-401.